{{Cite journal| doi = 10.1056/NEJMoa1904340| issn = 1533-4406| volume = 381| issue = 9| pages = 816–826| last = NAMSAL ANRS 12313 Study Group| title = Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1| journal = The New England Journal of Medicine| date = 2019-08-29}}